← Markets

Maravai LifeSciences Holdings, Inc.

MRVI · NASDAQ

Market closed$7.24$0.150000 (+2.12%)After hours $7.11 · -1.80%

Key statistics

Previous close$7.09
Open$6.91
Day high$7.26
Day low$6.81
52-week high$7.26
52-week low$1.99
Market cap2.00B
Volume2.84M
Average volume2.99M
P/E ratio-38.11
Forward P/E—
EPS-0.19
Dividend yield0.00%

Market context

Why it moved

MRVI's stock moved higher, buoyed by positive momentum after the biotech recently hit a 52-week high driven by key catalysts that renewed investor interest in the stock.

FacebookRobinhoodAiviouvapesThefridaytimesInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Maravai LifeSciences rose to touch a fresh 52-week high of $7.25 during the session, extending a remarkable YTD gain of over 117%, before slipping modestly in after-hours trading. The momentum reflects investor confidence following a strong Q1 2026 beat — revenue of $65.8M versus the $52.9M consensus and EPS of $0.01 vs. an expected loss — alongside a debt refinancing that improved the company's balance sheet. UBS has highlighted life sciences tools as entering a new earnings improvement cycle, providing broader sector tailwinds.

2.1157

July 17, 2026Maravai LifeSciences edged up modestly, closing near its 52-week high of $7.12, on above-average volume as the broader healthcare sector rallied. UnitedHealth Group's strong Q2 earnings beat and raised full-year guidance lifted sentiment across the healthcare space, while UBS upgraded its sector outlook, citing improving earnings revisions, a stabilizing regulatory environment, and the expectation that life science tools companies—like Maravai—are emerging from an inventory correction into a new phase of earnings improvement driven by AI adoption in drug discovery and diagnostics.

0.7102

July 16, 2026Maravai LifeSciences surged over 8%, touching its 52-week high, as the life science tools sector caught a tailwind from improving sentiment around the segment. UBS upgraded its outlook on healthcare, noting the life science tools sector is emerging from its inventory cycle into a new phase of earnings improvement, driven by accelerating AI adoption in drug discovery. The broader market also benefited from a softer-than-expected June CPI report, which eased rate-hike fears and lifted risk appetite across biotech and healthcare names.

8.1413

July 14, 2026Maravai LifeSciences shares rallied, closing near their 52-week high and trading modestly higher still in after-hours, outperforming a broadly cautious market weighed down by renewed U.S.-Iran tensions and oil price spikes. The gain comes as the broader biotech sector benefits from a Goldman Sachs-highlighted M&A wave and strong innovation tailwinds—dynamics that could favor life sciences tool providers like Maravai. Separately, a routine CEO tax-withholding event on RSU vesting was disclosed last week, carrying no open-market selling signal.

4.4335

July 11, 2026Maravai LifeSciences rose roughly 2% as the broader biotech sector continues to attract renewed investor interest, with CNBC's Jim Cramer calling biotech "the hottest group in the market right now" and the Health Care Sector ETF (XLV) pushing near record highs. The company's routine CEO equity compensation tax withholding event filed today drew no concern, while the broader narrative centers on life sciences tools exposure to mRNA and nucleic acid therapeutics — platforms investors are watching as the biotech rally broadens beyond mega-cap names.

2.0101

July 10, 2026Maravai LifeSciences closed up nearly 4%, riding a powerful wave of biotech sector enthusiasm as CNBC's Jim Cramer declared biotech "the hottest group in the market" and predicted a flood of M&A activity under the current FDA leadership. The healthcare sector (XLV) has been on a historic run — its best relative performance in over 15 years per one report — with health care leading all S&P 500 sectors for back-to-back weeks. As a life sciences tools company focused on mRNA, nucleic acid therapeutics, and advanced biologics, Maravai is well-positioned to benefit from renewed investor appetite for biotech-adjacent platforms and potential consolidation.

3.6458

July 9, 2026Maravai LifeSciences shares declined amid a broad market risk-off session, as escalating U.S.-Iran tensions sent oil prices surging more than 5% after President Trump declared the ceasefire agreement 'over,' weighing on equities broadly. Despite the macro headwinds, the broader biotech sector has been a market standout recently—Jim Cramer called it 'the hottest group in the market,' citing a favorable FDA regulatory shift and a coming wave of M&A deals, a backdrop that could support longer-term investor interest in life sciences tools and enabling technologies like those Maravai provides for mRNA and nucleic acid therapeutics.

-2.7027

July 7, 2026Maravai LifeSciences closed essentially unchanged in the regular session, edging up fractionally, before slipping about 2% in after-hours trade. The broader context is constructive for the biotech space, with Jim Cramer calling biotech "the hottest group in the market" and predicting a new wave of M&A as the regulatory environment under new FDA leadership has thawed dealmaking — a potential tailwind for smaller biotech tools and platform companies like Maravai. The healthcare sector (XLV) has been among the market's strongest performers recently, posting back-to-back leading weekly gains vs. the S&P 500, though the sector's earnings trajectory is projected to decline year-over-year near-term.

0.339

Stock Titan · June 16, 2026Inside the new enzyme plant speeding up next-gen RNA medicinesBusiness Wire · June 3, 2026Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032Simply Wall Street · May 14, 2026Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven OutlookBusiness Wire · May 7, 2026Maravai LifeSciences Reports First Quarter 2026 Financial Results
Mt Newswire · June 16, 2026Maravai Lifesciences Unit TriLink Opens Enzyme Manufacturing Facility in Florida
Mt Newswire · June 10, 2026Maravai Lifesciences Holdings Insider Sold Shares Worth $254,000, According to a Recent SEC Filing
Mt Newswire · June 3, 2026Maravai LifeSciences Refinances Credit Agreement, Extends Maturity to 2032
Benzinga · May 8, 2026Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5
Mt Newswire · May 8, 2026Deutsche Bank Adjusts Maravai Lifesciences Price Target to $6 From $4.50, Maintains Buy Rating
Benzinga · May 7, 2026Maravai LifeSciences Raises FY2026 Sales Guidance from $200.000M-$210.000M to $205.000M-$215.000M vs $204.933M Est
Benzinga · May 7, 2026Maravai LifeSciences Q1 Adj. EPS $0.01 Beats $(0.05) Estimate, Sales $65.837M Beat $53.046M Estimate
Benzinga · February 25, 2026Maravai LifeSciences Sees FY2026 Sales $200.000M-$210.000M vs $203.430M Est

Peers

S&P 500SPX · $7,457.69-1.01%Thermo Fisher Scientific Inc.TMO · $532.48-1.97%Sartorius AGSRT.DE · €193.40-1.53%Qiagen N.V.QGEN · $41.15-0.87%Twist Bioscience CorporationTWST · $93.85+2.87%Adaptive Biotechnologies CorporationADPT · $22.92+3.71%CRISPR Therapeutics AGCRSP · $47.78-1.63%Erasca, Inc.ERAS · $19.17+0.79%Amneal Pharmaceuticals, Inc.AMRX · $17.85-1.05%BioLife Solutions, Inc.BLFS · $29.15-3.67%Repligen CorporationRGEN · $147.25-0.88%Agilent Technologies, Inc.A · $131.46-3.41%